> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Medetomidine appeared in about a quarter of Southern California fentanyl samples by 2026
- URL: https://www.coios.me/medetomidine-appeared-in-about-a-quarter-of-southern/
- Published: 2026-10-25T11:57:41.000Z
- Updated: 2026-10-25T12:37:42.000Z
- Description: Medetomidine was first detected in Southern California fentanyl in May 2025 and was present in about 25% by August 2026.
- Author: Daniel Ryan
- Tags: Behavioural science, Alcohol and drug use, United States, #preprint, #new, #item, #source-2026-10, #score-70

The study characterised medetomidine in drug samples given anonymously to a Southern California drug checking programme from 2023 to 2026\. All samples underwent DART-MS, a subset was quantified by LC-MS/MS, and 13 underwent enantiomeric analysis. Medetomidine's quarterly prevalence in fentanyl samples rose from about 6% in May 2025 to about 25% by August 2026\. Mean concentration was 0.4% mass fraction, and all 13 tested samples were racemic, an equal mix of both enantiomers. The substances most often detected with medetomidine were fentanyl and the adulterants lidocaine and xylazine. Samples were given voluntarily to one programme, and only 13 underwent enantiomeric analysis.

*Why it is interesting: Medetomidine was previously described mostly in eastern US fentanyl markets. All tested samples were racemic, suggesting they were not diverted from human pharmaceutical or medical supplies.*

Source

[medRxiv, 22 October 2026](https://doi.org/10.64898/2026.10.13.26365459?ref=coios.me)

Paper

Characterizing the Emergence of Medetomidine in Southern California Fentanyl Markets

Authors

Koncsol AJ, Friedman JR, Molina CA, Grabill M, Godvin ME, Romero R et al.

DOI

10.64898/2026.10.13.26365459

Type

Preprint

Design

Community drug-checking programme samples, Southern California 2023-2026, DART-MS with LC-MS/MS subset and enantiomeric analysis (n=13)

Verdict

New finding

Driver

[Alcohol and drug use](https://www.coios.me/d-alcohol-drugs/)

Abstract — the authors' own words, CC BY

Background:

Medetomidine, a potent sedative, is increasingly present in fentanyl-related hospitalizations and deaths. Multiple states have passed legislation to control xylazine, a pharmacologically similar sedative in the illicit opioid supply. Medetomidine may function as a highly potent substitute for xylazine with significant overdose risk and withdrawal potential. Medetomidine has previously been described mostly in eastern U.S. fentanyl markets. Here, we characterize medetomidine-containing drug samples obtained in Southern California 2023-2026\. Methods:

Anonymous participants in Southern California voluntarily provided drug products to a community-based drug checking program. All samples underwent direct-analysis-in-real-time mass spectrometry (DART-MS). A subset was quantified by liquid-chromatography tandem mass spectrometry (LC-MS/MS). A smaller subset underwent enantiomeric analysis. We calculated other compounds co-present with medetomidine, the prevalence of medetomidine in fentanyl over time, the concentration of medetomidine, and the enantiomer makeup of medetomidine. Results:

The quarterly prevalence of medetomidine co-present with fentanyl rose from ≈6 % in May 2025 (month of first detection) to ≈25 % by August 2026\. The average medetomidine concentration was 0.4 % mass fraction. The most common co-detected substances with medetomidine were fentanyl and adulterants such as lidocaine and xylazine. All medetomidine samples that underwent enantiomeric analysis (n = 13) were identified as racemic. Conclusion:

Medetomidine represents a rapidly emerging adulterant in the Southern California fentanyl supply. All samples assessed for enantiomer status were racemic medetomidine, suggesting they were not diverted from human pharmaceutical or medical supplies. Given its high potency, a small amount (<1.5%) is likely still a physiologically significant quantity of the drug.